Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay


SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, molecular residual disease (MRD) assay to market.

Continued here:
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Related Posts